相似文献
1
Furthering research on MAFLD: the APASL Metabolic fAtty lIver DiseasE coNsortium (MAIDEN).
Hepatol Int. 2023 Jun;17(3):546-549. doi: 10.1007/s12072-023-10530-z. Epub 2023 Apr 20.
2
MAFLD, patient-centred care, and APASL.
Hepatol Int. 2022 Oct;16(5):1032-1034. doi: 10.1007/s12072-022-10408-6. Epub 2022 Sep 7.
3
Characterization of Gut Microbiome in Korean Patients with Metabolic Associated Fatty Liver Disease.
Nutrients. 2021 Mar 21;13(3):1013. doi: 10.3390/nu13031013.
4
Metabolic dysfunction associated fatty liver disease (MAFLD) and serum vitamin D concentration in South Korea.
Asia Pac J Clin Nutr. 2022;31(2):201-207. doi: 10.6133/apjcn.202206_31(2).0005.
5
Long-term cardiovascular outcomes differ across metabolic dysfunction-associated fatty liver disease subtypes among middle-aged population.
Hepatol Int. 2022 Dec;16(6):1308-1317. doi: 10.1007/s12072-022-10407-7. Epub 2022 Sep 7.
6
Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non-alcoholic fatty liver disease.
Liver Int. 2023 Mar;43(3):608-625. doi: 10.1111/liv.15508. Epub 2023 Jan 11.
7
Associations of metal mixtures with metabolic-associated fatty liver disease and non-alcoholic fatty liver disease: NHANES 2003-2018.
Front Public Health. 2023 Mar 6;11:1133194. doi: 10.3389/fpubh.2023.1133194. eCollection 2023.
8
Curcumin and Biochemical Parameters in Metabolic-Associated Fatty Liver Disease (MAFLD)-A Review.
Nutrients. 2021 Jul 30;13(8):2654. doi: 10.3390/nu13082654.
9
Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan.
J Gastroenterol. 2021 Nov;56(11):1022-1032. doi: 10.1007/s00535-021-01828-6. Epub 2021 Oct 3.
10
Remnant Cholesterol Predicts Long-term Mortality of Patients With Metabolic Dysfunction-associated Fatty Liver Disease.
J Clin Endocrinol Metab. 2022 Jul 14;107(8):e3295-e3303. doi: 10.1210/clinem/dgac283.
引用本文的文献
1
HOMA-IR, an independent predictor of advanced liver fibrosis in metabolic-dysfunction associated fatty liver disease: a cross-sectional study in Egyptian patients.
Sci Rep. 2025 Aug 24;15(1):31098. doi: 10.1038/s41598-025-15425-7.
2
HEPNET Position Statement-I, Case Definition, Classification, Screening & Diagnosis of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Pakistan: A Resource for Primary and Secondary Care Physicians.
Pak J Med Sci. 2025 Mar;41(3):929-938. doi: 10.12669/pjms.41.3.10081.
本文引用的文献
1
Microbiome-derived ethanol in nonalcoholic fatty liver disease.
Nat Med. 2022 Oct;28(10):2100-2106. doi: 10.1038/s41591-022-02016-6. Epub 2022 Oct 10.
2
Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight.
Nat Rev Gastroenterol Hepatol. 2022 Oct;19(10):638-651. doi: 10.1038/s41575-022-00635-5. Epub 2022 Jun 16.
3
A new risk stratification strategy for fatty liver disease by incorporating MAFLD and fibrosis score in a large US population.
Hepatol Int. 2022 Aug;16(4):835-845. doi: 10.1007/s12072-022-10362-3. Epub 2022 Jun 14.
4
Impact of non-invasive biomarkers on hepatology practice: Past, present and future.
J Hepatol. 2022 Jun;76(6):1362-1378. doi: 10.1016/j.jhep.2022.03.026.
5
Prevalence and characteristics of MAFLD in Chinese adults aged 40 years or older: A community-based study.
Hepatobiliary Pancreat Dis Int. 2022 Apr;21(2):154-161. doi: 10.1016/j.hbpd.2022.01.006. Epub 2022 Jan 31.
6
Metabolic Dysfunction-Associated Fatty Liver Disease Increases Colon Cancer Risk: A Nationwide Cohort Study.
Clin Transl Gastroenterol. 2022 Jan 12;13(1):e00435. doi: 10.14309/ctg.0000000000000435.
7
The importance and impact of recognizing metabolic dysfunction-associated fatty liver disease in patients with chronic hepatitis C.
J Dig Dis. 2022 Jan;23(1):33-43. doi: 10.1111/1751-2980.13071.
8
Metabolic associated fatty liver disease is a risk factor for chronic kidney disease.
J Diabetes Investig. 2022 Feb;13(2):308-316. doi: 10.1111/jdi.13678. Epub 2021 Oct 12.
9
Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States.
J Hepatol. 2021 Dec;75(6):1284-1291. doi: 10.1016/j.jhep.2021.07.035. Epub 2021 Aug 8.
10
Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement.
Lancet Gastroenterol Hepatol. 2021 Oct;6(10):864-873. doi: 10.1016/S2468-1253(21)00183-7. Epub 2021 Aug 6.
Zotero 插件